ArticleRadiation oncology (London, England)2025
Exploring the impact of pelvic radiotherapy dose distribution on lymphocyte counts: a voxel-based analysis.
Article in Radiation oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Immune-sparing radiotherapy in solid tumors: radiation-induced lymphopenia, circulating immune-cell dose, and biomarker-guided optimization of radioimmunotherapy.Journal of cancer research and clinical oncology · 2026Review
- Bone Marrow-Sparing Pelvic Radiotherapy: Clinical Evidence, Dosimetric Constraints, and Clinical Outcomes.Cureus · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
background and purposeThis study aimed to evaluate the impact of pelvic radiation therapy (RT) on the occurrence of severe radiation-induced lymphopenia (SRIL) and identify its clinical and dosimetric predictors using voxel-wise analysis. Understanding these impacts is crucial for improving patient outcomes and optimizing treatment protocols in radiation oncology. MATERIALS AND
methodsA retrospective analysis was conducted on 122 patients who underwent pelvic RT. Absolute lymphocyte counts (ALC) were measured before treatment and within one month of RT initiation. Patients were classified into SRIL and non-SRIL groups on the basis of their lowest recorded ALC during treatment. The associations between SRIL and clinical/dosimetric parameters were assessed via univariable (UVA) and multivariate (MVA) analysis. The influence of regionally detailed dose was assessed by voxel-based analysis (VBA) on spatially normalized 3D dose maps and CT images, focusing on the sacrum, femoral heads, and pelvic bones.
resultsSRIL was associated with clinical and dosimetric factors. The baseline ALC was the most significant clinical predictor, with a lower baseline ALC increasing SRIL risk (OR = 0.996, p = 0.001). VBA further revealed localized highly related regional dose patterns, with 92.17% of the left femoral head and 91.32% of the right femoral head showing significant SRIL associations, whereas the associations were significantly lower in the sacrum (10.39%) and pelvic bones (left: 30.01%, right: 31.52%).
conclusionThis study identified key clinical and dosimetric factors influencing SRIL in patients undergoing pelvic radiotherapy. Baseline ALC was the most significant clinical factor, and VBA showed that regional dose pattern changes within the femoral head were significantly associated with SRIL. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.